Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance

被引：61

作者：

Rajkumar, SV

Kyle, RA

Therneau, TM

Clark, RJ

Bradwell, AR

Melton, LJ

Larson, DR

Plevak, MF

Katzmann, JA

机构：

[1] Mayo Clin & Mayo Fdn, Coll Med, Div Hematol, Rochester, MN 55905 USA

[2] Mayo Clin & Mayo Fdn, Coll Med, Div Biostat, Rochester, MN 55905 USA

[3] Mayo Clin & Mayo Fdn, Coll Med, Div Epidemiol, Rochester, MN 55905 USA

[4] Mayo Clin & Mayo Fdn, Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA

[5] Univ Birmingham, Birmingham, W Midlands, England

[6] Binding Site Ltd, Birmingham, W Midlands, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2004年 / 127卷 / 03期

关键词：

monoclonal gammopathy of undetermined significance; progression; kappa light chains; lambda light chains; kappa; lambda free light chain ratio;

D O I：

10.1111/j.1365-2141.2004.05169.x

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

We hypothesized that the presence of monoclonal free light chains (FLC) in the serum of patients with monoclonal gammopathy of undetermined significance (MGUS) is a marker of clonal evolution and a risk factor for progression. Forty-seven patients with MGUS and documented progression to myeloma or related malignancy were compared with 50 age- and gender-matched patients with MGUS and no evidence of progression after 5 or more years of follow-up. The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2.5; 95% confidence interval: 1.6-4.0; P < 0.001).

引用

页码：308 / 310

页数：3

共 11 条

[1]

Abraham RS, 2002, CLIN CHEM, V48, P655

[2]

Serum test for assessment of patients with Bence Jones myeloma [J].